nodes	percent_of_prediction	percent_of_DWPC	metapath
Temsirolimus—ABCB1—Lisinopril—systemic scleroderma	0.084	0.189	CbGbCtD
Temsirolimus—CYP3A5—Mycophenolate mofetil—systemic scleroderma	0.076	0.171	CbGbCtD
Temsirolimus—ABCB1—Captopril—systemic scleroderma	0.0629	0.141	CbGbCtD
Temsirolimus—CYP2D6—Captopril—systemic scleroderma	0.0592	0.133	CbGbCtD
Temsirolimus—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0495	0.111	CbGbCtD
Temsirolimus—ABCB1—Prednisone—systemic scleroderma	0.0396	0.089	CbGbCtD
Temsirolimus—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.0297	0.0667	CbGbCtD
Temsirolimus—CYP3A4—Prednisone—systemic scleroderma	0.0237	0.0534	CbGbCtD
Temsirolimus—ABCB1—Methotrexate—systemic scleroderma	0.0198	0.0447	CbGbCtD
Temsirolimus—FKBP1A—ALK1 signaling events—SMAD7—systemic scleroderma	0.00618	0.0673	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—SMAD7—systemic scleroderma	0.00524	0.057	CbGpPWpGaD
Temsirolimus—MTOR—TSLP Signaling Pathway—TNFSF4—systemic scleroderma	0.00412	0.0448	CbGpPWpGaD
Temsirolimus—MTOR—blood vessel—systemic scleroderma	0.00378	0.153	CbGeAlD
Temsirolimus—FKBP1A—TGF-beta receptor signaling—SMAD7—systemic scleroderma	0.00355	0.0386	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—AIF1—systemic scleroderma	0.00351	0.0382	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta Receptor Signaling—SMAD7—systemic scleroderma	0.00344	0.0375	CbGpPWpGaD
Temsirolimus—FKBP1A—Alpha-synuclein signaling—BLK—systemic scleroderma	0.00329	0.0358	CbGpPWpGaD
Temsirolimus—MTOR—EGFR-dependent Endothelin signaling events—EDN1—systemic scleroderma	0.00321	0.0349	CbGpPWpGaD
Temsirolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—SMAD7—systemic scleroderma	0.0028	0.0305	CbGpPWpGaD
Temsirolimus—MTOR—IFN-gamma pathway—SMAD7—systemic scleroderma	0.00232	0.0253	CbGpPWpGaD
Temsirolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—CD40LG—systemic scleroderma	0.00221	0.0241	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta receptor signaling—CTGF—systemic scleroderma	0.00196	0.0214	CbGpPWpGaD
Temsirolimus—MTOR—connective tissue—systemic scleroderma	0.00194	0.0785	CbGeAlD
Temsirolimus—MTOR—smooth muscle tissue—systemic scleroderma	0.00177	0.0718	CbGeAlD
Temsirolimus—MTOR—skin of body—systemic scleroderma	0.00175	0.0708	CbGeAlD
Temsirolimus—FKBP1A—connective tissue—systemic scleroderma	0.00174	0.0706	CbGeAlD
Temsirolimus—FKBP1A—Spinal Cord Injury—TNFSF13—systemic scleroderma	0.00171	0.0186	CbGpPWpGaD
Temsirolimus—FKBP1A—smooth muscle tissue—systemic scleroderma	0.00159	0.0646	CbGeAlD
Temsirolimus—FKBP1A—skin of body—systemic scleroderma	0.00157	0.0637	CbGeAlD
Temsirolimus—FKBP1A—Spinal Cord Injury—SELP—systemic scleroderma	0.00153	0.0166	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition)—TGFB1—systemic scleroderma	0.00145	0.0158	CbGpPWpGaD
Temsirolimus—MTOR—IL4-mediated signaling events—SELP—systemic scleroderma	0.00144	0.0156	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—RHOB—systemic scleroderma	0.00143	0.0155	CbGpPWpGaD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.00141	0.0153	CbGpPWpGaD
Temsirolimus—MTOR—digestive system—systemic scleroderma	0.0014	0.0567	CbGeAlD
Temsirolimus—MTOR—tendon—systemic scleroderma	0.00133	0.0539	CbGeAlD
Temsirolimus—MTOR—IL4-mediated signaling events—COL1A2—systemic scleroderma	0.00127	0.0138	CbGpPWpGaD
Temsirolimus—MTOR—TSLP Signaling Pathway—STAT4—systemic scleroderma	0.00126	0.0137	CbGpPWpGaD
Temsirolimus—FKBP1A—digestive system—systemic scleroderma	0.00126	0.051	CbGeAlD
Temsirolimus—FKBP1A—tendon—systemic scleroderma	0.0012	0.0485	CbGeAlD
Temsirolimus—MTOR—IL12-mediated signaling events—CD247—systemic scleroderma	0.00118	0.0128	CbGpPWpGaD
Temsirolimus—MTOR—lung—systemic scleroderma	0.00117	0.0473	CbGeAlD
Temsirolimus—MTOR—Costimulation by the CD28 family—CSK—systemic scleroderma	0.00114	0.0124	CbGpPWpGaD
Temsirolimus—MTOR—Interferon type I signaling pathways—STAT4—systemic scleroderma	0.00113	0.0123	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—CD247—systemic scleroderma	0.00107	0.0116	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—RHOB—systemic scleroderma	0.00105	0.0115	CbGpPWpGaD
Temsirolimus—FKBP1A—lung—systemic scleroderma	0.00105	0.0426	CbGeAlD
Temsirolimus—MTOR—IL12-mediated signaling events—STAT4—systemic scleroderma	0.00104	0.0113	CbGpPWpGaD
Temsirolimus—FKBP1A—ALK1 signaling events—TGFB1—systemic scleroderma	0.000984	0.0107	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—CSK—systemic scleroderma	0.000959	0.0104	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—CD247—systemic scleroderma	0.000901	0.00981	CbGpPWpGaD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—SMAD7—systemic scleroderma	0.000851	0.00926	CbGpPWpGaD
Temsirolimus—MTOR—CXCR4-mediated signaling events—BLK—systemic scleroderma	0.000834	0.00907	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta receptor signaling activates SMADs—TGFB1—systemic scleroderma	0.000833	0.00907	CbGpPWpGaD
Temsirolimus—MTOR—GAB1 signalosome—CSK—systemic scleroderma	0.000821	0.00893	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—CTLA4—systemic scleroderma	0.000809	0.0088	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—IRF5—systemic scleroderma	0.000789	0.00858	CbGpPWpGaD
Temsirolimus—MTOR—VEGFR2 mediated vascular permeability—NOS3—systemic scleroderma	0.000788	0.00858	CbGpPWpGaD
Temsirolimus—ABCB1—blood vessel—systemic scleroderma	0.000786	0.0318	CbGeAlD
Temsirolimus—FKBP1A—Spinal Cord Injury—IL1A—systemic scleroderma	0.000724	0.00788	CbGpPWpGaD
Temsirolimus—MTOR—IL4-mediated signaling events—CD40LG—systemic scleroderma	0.000677	0.00737	CbGpPWpGaD
Temsirolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—systemic scleroderma	0.000666	0.00725	CbGpPWpGaD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—CSK—systemic scleroderma	0.000567	0.00617	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta receptor signaling—TGFB1—systemic scleroderma	0.000565	0.00615	CbGpPWpGaD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—MMP1—systemic scleroderma	0.000554	0.00603	CbGpPWpGaD
Temsirolimus—FKBP1A—TGF-beta Receptor Signaling—TGFB1—systemic scleroderma	0.000548	0.00596	CbGpPWpGaD
Temsirolimus—CYP3A5—digestive system—systemic scleroderma	0.000548	0.0222	CbGeAlD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—EDN1—systemic scleroderma	0.000537	0.00585	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR—CSK—systemic scleroderma	0.000523	0.00569	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by EGFR in Cancer—CSK—systemic scleroderma	0.000519	0.00564	CbGpPWpGaD
Temsirolimus—CYP2D6—Melatonin metabolism and effects—EDN1—systemic scleroderma	0.00051	0.00555	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—CCL2—systemic scleroderma	0.000498	0.00542	CbGpPWpGaD
Temsirolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—TGFB1—systemic scleroderma	0.000493	0.00537	CbGpPWpGaD
Temsirolimus—MTOR—IFN-gamma pathway—IL1B—systemic scleroderma	0.000476	0.00518	CbGpPWpGaD
Temsirolimus—CYP3A5—lung—systemic scleroderma	0.000457	0.0185	CbGeAlD
Temsirolimus—MTOR—Oncostatin M Signaling Pathway—CCL2—systemic scleroderma	0.000451	0.00491	CbGpPWpGaD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—IL1A—systemic scleroderma	0.000447	0.00486	CbGpPWpGaD
Temsirolimus—FKBP1A—Loss of Function of SMAD2/3 in Cancer—TGFB1—systemic scleroderma	0.000445	0.00485	CbGpPWpGaD
Temsirolimus—MTOR—B Cell Activation—BLK—systemic scleroderma	0.000425	0.00463	CbGpPWpGaD
Temsirolimus—CYP3A4—digestive system—systemic scleroderma	0.000411	0.0167	CbGeAlD
Temsirolimus—CYP2D6—digestive system—systemic scleroderma	0.000404	0.0164	CbGeAlD
Temsirolimus—ABCB1—Allograft Rejection—IL13—systemic scleroderma	0.000384	0.00418	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—IL1B—systemic scleroderma	0.000377	0.00411	CbGpPWpGaD
Temsirolimus—MTOR—IL12-mediated signaling events—IL1B—systemic scleroderma	0.000365	0.00397	CbGpPWpGaD
Temsirolimus—MTOR—Leptin signaling pathway—NOS3—systemic scleroderma	0.000358	0.0039	CbGpPWpGaD
Temsirolimus—FKBP1A—Spinal Cord Injury—MMP9—systemic scleroderma	0.000356	0.00387	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TOP1—systemic scleroderma	0.000341	0.00371	CbGpPWpGaD
Temsirolimus—Gastrointestinal disorder—Azathioprine—systemic scleroderma	0.000321	0.00073	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Leflunomide—systemic scleroderma	0.00032	0.000728	CcSEcCtD
Temsirolimus—Anorexia—Mycophenolic acid—systemic scleroderma	0.000319	0.000726	CcSEcCtD
Temsirolimus—Insomnia—Leflunomide—systemic scleroderma	0.000317	0.000722	CcSEcCtD
Temsirolimus—Abdominal distension—Prednisone—systemic scleroderma	0.000317	0.000722	CcSEcCtD
Temsirolimus—Dysgeusia—Mycophenolate mofetil—systemic scleroderma	0.000317	0.000721	CcSEcCtD
Temsirolimus—Chest pain—Lisinopril—systemic scleroderma	0.000314	0.000716	CcSEcCtD
Temsirolimus—Myalgia—Lisinopril—systemic scleroderma	0.000314	0.000716	CcSEcCtD
Temsirolimus—Arthralgia—Lisinopril—systemic scleroderma	0.000314	0.000716	CcSEcCtD
Temsirolimus—Anxiety—Lisinopril—systemic scleroderma	0.000313	0.000713	CcSEcCtD
Temsirolimus—Back pain—Mycophenolate mofetil—systemic scleroderma	0.000313	0.000713	CcSEcCtD
Temsirolimus—Dyspnoea—Leflunomide—systemic scleroderma	0.000313	0.000712	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—systemic scleroderma	0.000312	0.000711	CcSEcCtD
Temsirolimus—ABCB1—Allograft Rejection—CTLA4—systemic scleroderma	0.000309	0.00336	CbGpPWpGaD
Temsirolimus—Vomiting—Mometasone—systemic scleroderma	0.000308	0.000701	CcSEcCtD
Temsirolimus—Rash—Mometasone—systemic scleroderma	0.000305	0.000696	CcSEcCtD
Temsirolimus—Asthenia—Captopril—systemic scleroderma	0.000305	0.000695	CcSEcCtD
Temsirolimus—Dermatitis—Mometasone—systemic scleroderma	0.000305	0.000695	CcSEcCtD
Temsirolimus—MTOR—Leptin signaling pathway—IL1B—systemic scleroderma	0.000305	0.00332	CbGpPWpGaD
Temsirolimus—Decreased appetite—Leflunomide—systemic scleroderma	0.000305	0.000694	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Mycophenolic acid—systemic scleroderma	0.000305	0.000694	CcSEcCtD
Temsirolimus—MTOR—Cardiac Hypertrophic Response—TGFB1—systemic scleroderma	0.000304	0.00331	CbGpPWpGaD
Temsirolimus—Gastrointestinal pain—Azathioprine—systemic scleroderma	0.000304	0.000692	CcSEcCtD
Temsirolimus—Headache—Mometasone—systemic scleroderma	0.000304	0.000691	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Leflunomide—systemic scleroderma	0.000303	0.000689	CcSEcCtD
Temsirolimus—Insomnia—Mycophenolic acid—systemic scleroderma	0.000303	0.000689	CcSEcCtD
Temsirolimus—Fatigue—Leflunomide—systemic scleroderma	0.000302	0.000689	CcSEcCtD
Temsirolimus—Oedema—Lisinopril—systemic scleroderma	0.000301	0.000686	CcSEcCtD
Temsirolimus—Anaphylactic shock—Lisinopril—systemic scleroderma	0.000301	0.000686	CcSEcCtD
Temsirolimus—Pruritus—Captopril—systemic scleroderma	0.000301	0.000686	CcSEcCtD
Temsirolimus—Pain—Leflunomide—systemic scleroderma	0.0003	0.000683	CcSEcCtD
Temsirolimus—Constipation—Leflunomide—systemic scleroderma	0.0003	0.000683	CcSEcCtD
Temsirolimus—Infection—Lisinopril—systemic scleroderma	0.000299	0.000682	CcSEcCtD
Temsirolimus—Anaemia—Mycophenolate mofetil—systemic scleroderma	0.000299	0.000681	CcSEcCtD
Temsirolimus—Dyspnoea—Mycophenolic acid—systemic scleroderma	0.000298	0.000679	CcSEcCtD
Temsirolimus—Somnolence—Mycophenolic acid—systemic scleroderma	0.000297	0.000677	CcSEcCtD
Temsirolimus—Angioedema—Mycophenolate mofetil—systemic scleroderma	0.000296	0.000673	CcSEcCtD
Temsirolimus—Thrombocytopenia—Lisinopril—systemic scleroderma	0.000295	0.000672	CcSEcCtD
Temsirolimus—Neutropenia—Prednisone—systemic scleroderma	0.000294	0.00067	CcSEcCtD
Temsirolimus—Abdominal pain—Azathioprine—systemic scleroderma	0.000294	0.000669	CcSEcCtD
Temsirolimus—Body temperature increased—Azathioprine—systemic scleroderma	0.000294	0.000669	CcSEcCtD
Temsirolimus—FKBP1A—Spinal Cord Injury—TGFB1—systemic scleroderma	0.000293	0.00319	CbGpPWpGaD
Temsirolimus—Skin disorder—Lisinopril—systemic scleroderma	0.000293	0.000667	CcSEcCtD
Temsirolimus—Diarrhoea—Captopril—systemic scleroderma	0.000291	0.000663	CcSEcCtD
Temsirolimus—ABCB1—digestive system—systemic scleroderma	0.000291	0.0118	CbGeAlD
Temsirolimus—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000291	0.000662	CcSEcCtD
Temsirolimus—Leukopenia—Mycophenolate mofetil—systemic scleroderma	0.00029	0.000659	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000289	0.000658	CcSEcCtD
Temsirolimus—Fatigue—Mycophenolic acid—systemic scleroderma	0.000288	0.000657	CcSEcCtD
Temsirolimus—Nausea—Mometasone—systemic scleroderma	0.000288	0.000655	CcSEcCtD
Temsirolimus—Anorexia—Lisinopril—systemic scleroderma	0.000287	0.000654	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000287	0.000653	CcSEcCtD
Temsirolimus—Pain—Mycophenolic acid—systemic scleroderma	0.000286	0.000652	CcSEcCtD
Temsirolimus—Constipation—Mycophenolic acid—systemic scleroderma	0.000286	0.000652	CcSEcCtD
Temsirolimus—Weight decreased—Prednisone—systemic scleroderma	0.000285	0.000648	CcSEcCtD
Temsirolimus—Hyperglycaemia—Prednisone—systemic scleroderma	0.000284	0.000647	CcSEcCtD
Temsirolimus—MTOR—Integrated Breast Cancer Pathway—MMP1—systemic scleroderma	0.000283	0.00307	CbGpPWpGaD
Temsirolimus—Cough—Mycophenolate mofetil—systemic scleroderma	0.000282	0.000643	CcSEcCtD
Temsirolimus—Dizziness—Captopril—systemic scleroderma	0.000281	0.000641	CcSEcCtD
Temsirolimus—ABCB1—HIF-1-alpha transcription factor network—EDN1—systemic scleroderma	0.000281	0.00305	CbGpPWpGaD
Temsirolimus—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.00028	0.000638	CcSEcCtD
Temsirolimus—Depression—Prednisone—systemic scleroderma	0.00028	0.000637	CcSEcCtD
Temsirolimus—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000279	0.000636	CcSEcCtD
Temsirolimus—FKBP1A—Disease—SMAD7—systemic scleroderma	0.000278	0.00303	CbGpPWpGaD
Temsirolimus—Body temperature increased—Leflunomide—systemic scleroderma	0.000277	0.000631	CcSEcCtD
Temsirolimus—Abdominal pain—Leflunomide—systemic scleroderma	0.000277	0.000631	CcSEcCtD
Temsirolimus—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000627	CcSEcCtD
Temsirolimus—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000627	CcSEcCtD
Temsirolimus—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000275	0.000627	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000275	0.000625	CcSEcCtD
Temsirolimus—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000274	0.000625	CcSEcCtD
Temsirolimus—Hypersensitivity—Azathioprine—systemic scleroderma	0.000274	0.000623	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.000274	0.000623	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.000274	0.000623	CcSEcCtD
Temsirolimus—Insomnia—Lisinopril—systemic scleroderma	0.000273	0.000621	CcSEcCtD
Temsirolimus—Vomiting—Captopril—systemic scleroderma	0.000271	0.000616	CcSEcCtD
Temsirolimus—MTOR—VEGFA-VEGFR2 Pathway—NOS3—systemic scleroderma	0.00027	0.00294	CbGpPWpGaD
Temsirolimus—Dyspnoea—Lisinopril—systemic scleroderma	0.000269	0.000612	CcSEcCtD
Temsirolimus—Rash—Captopril—systemic scleroderma	0.000268	0.000611	CcSEcCtD
Temsirolimus—Dermatitis—Captopril—systemic scleroderma	0.000268	0.00061	CcSEcCtD
Temsirolimus—Somnolence—Lisinopril—systemic scleroderma	0.000268	0.00061	CcSEcCtD
Temsirolimus—Headache—Captopril—systemic scleroderma	0.000267	0.000607	CcSEcCtD
Temsirolimus—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000264	0.000602	CcSEcCtD
Temsirolimus—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000264	0.000602	CcSEcCtD
Temsirolimus—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000264	0.000601	CcSEcCtD
Temsirolimus—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000264	0.000601	CcSEcCtD
Temsirolimus—MTOR—CXCR4-mediated signaling events—MMP9—systemic scleroderma	0.000263	0.00286	CbGpPWpGaD
Temsirolimus—Infection—Mycophenolate mofetil—systemic scleroderma	0.000262	0.000597	CcSEcCtD
Temsirolimus—Decreased appetite—Lisinopril—systemic scleroderma	0.000262	0.000597	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.00026	0.000592	CcSEcCtD
Temsirolimus—Fatigue—Lisinopril—systemic scleroderma	0.00026	0.000592	CcSEcCtD
Temsirolimus—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.000259	0.00059	CcSEcCtD
Temsirolimus—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	0.000259	0.000589	CcSEcCtD
Temsirolimus—Hypersensitivity—Leflunomide—systemic scleroderma	0.000258	0.000588	CcSEcCtD
Temsirolimus—Constipation—Lisinopril—systemic scleroderma	0.000258	0.000587	CcSEcCtD
Temsirolimus—Pain—Lisinopril—systemic scleroderma	0.000258	0.000587	CcSEcCtD
Temsirolimus—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000256	0.000584	CcSEcCtD
Temsirolimus—MTOR—Regulation of Telomerase—TGFB1—systemic scleroderma	0.000256	0.00279	CbGpPWpGaD
Temsirolimus—MTOR—Signaling by VEGF—NOS3—systemic scleroderma	0.000255	0.00277	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TGFBI—systemic scleroderma	0.000255	0.00277	CbGpPWpGaD
Temsirolimus—ABCB1—Allograft Rejection—HLA-DQB1—systemic scleroderma	0.000254	0.00277	CbGpPWpGaD
Temsirolimus—Diarrhoea—Azathioprine—systemic scleroderma	0.000254	0.000579	CcSEcCtD
Temsirolimus—Nausea—Captopril—systemic scleroderma	0.000253	0.000576	CcSEcCtD
Temsirolimus—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000252	0.000573	CcSEcCtD
Temsirolimus—Asthenia—Leflunomide—systemic scleroderma	0.000252	0.000573	CcSEcCtD
Temsirolimus—Pruritus—Leflunomide—systemic scleroderma	0.000248	0.000565	CcSEcCtD
Temsirolimus—Connective tissue disorder—Prednisone—systemic scleroderma	0.000248	0.000564	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000246	0.000561	CcSEcCtD
Temsirolimus—Dysuria—Methotrexate—systemic scleroderma	0.000246	0.00056	CcSEcCtD
Temsirolimus—Neutropenia—Methotrexate—systemic scleroderma	0.000246	0.00056	CcSEcCtD
Temsirolimus—Dizziness—Azathioprine—systemic scleroderma	0.000246	0.000559	CcSEcCtD
Temsirolimus—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.000244	0.000557	CcSEcCtD
Temsirolimus—ABCB1—lung—systemic scleroderma	0.000243	0.00985	CbGeAlD
Temsirolimus—ABCB1—Allograft Rejection—IL1A—systemic scleroderma	0.000242	0.00263	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000241	0.000548	CcSEcCtD
Temsirolimus—ABCB1—Allograft Rejection—CD40LG—systemic scleroderma	0.00024	0.00261	CbGpPWpGaD
Temsirolimus—Asthenia—Mycophenolic acid—systemic scleroderma	0.00024	0.000547	CcSEcCtD
Temsirolimus—Diarrhoea—Leflunomide—systemic scleroderma	0.00024	0.000546	CcSEcCtD
Temsirolimus—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000239	0.000544	CcSEcCtD
Temsirolimus—Abdominal pain—Lisinopril—systemic scleroderma	0.000238	0.000542	CcSEcCtD
Temsirolimus—Body temperature increased—Lisinopril—systemic scleroderma	0.000238	0.000542	CcSEcCtD
Temsirolimus—Pruritus—Mycophenolic acid—systemic scleroderma	0.000237	0.000539	CcSEcCtD
Temsirolimus—Vomiting—Azathioprine—systemic scleroderma	0.000236	0.000538	CcSEcCtD
Temsirolimus—Pneumonia—Methotrexate—systemic scleroderma	0.000236	0.000537	CcSEcCtD
Temsirolimus—Eye disorder—Prednisone—systemic scleroderma	0.000235	0.000536	CcSEcCtD
Temsirolimus—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000536	CcSEcCtD
Temsirolimus—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000235	0.000535	CcSEcCtD
Temsirolimus—Infestation NOS—Methotrexate—systemic scleroderma	0.000235	0.000534	CcSEcCtD
Temsirolimus—Infestation—Methotrexate—systemic scleroderma	0.000235	0.000534	CcSEcCtD
Temsirolimus—Rash—Azathioprine—systemic scleroderma	0.000234	0.000533	CcSEcCtD
Temsirolimus—Dermatitis—Azathioprine—systemic scleroderma	0.000234	0.000533	CcSEcCtD
Temsirolimus—Depression—Methotrexate—systemic scleroderma	0.000234	0.000533	CcSEcCtD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—IL1B—systemic scleroderma	0.000233	0.00254	CbGpPWpGaD
Temsirolimus—Headache—Azathioprine—systemic scleroderma	0.000233	0.00053	CcSEcCtD
Temsirolimus—Stevens-Johnson syndrome—Methotrexate—systemic scleroderma	0.000233	0.000529	CcSEcCtD
Temsirolimus—Dizziness—Leflunomide—systemic scleroderma	0.000232	0.000528	CcSEcCtD
Temsirolimus—Renal failure—Methotrexate—systemic scleroderma	0.000231	0.000525	CcSEcCtD
Temsirolimus—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.00023	0.000523	CcSEcCtD
Temsirolimus—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000229	0.000521	CcSEcCtD
Temsirolimus—Stomatitis—Methotrexate—systemic scleroderma	0.000229	0.000521	CcSEcCtD
Temsirolimus—Angiopathy—Prednisone—systemic scleroderma	0.000229	0.00052	CcSEcCtD
Temsirolimus—Conjunctivitis—Methotrexate—systemic scleroderma	0.000228	0.000519	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000228	0.000519	CcSEcCtD
Temsirolimus—Immune system disorder—Prednisone—systemic scleroderma	0.000228	0.000518	CcSEcCtD
Temsirolimus—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000514	CcSEcCtD
Temsirolimus—Pain—Mycophenolate mofetil—systemic scleroderma	0.000226	0.000514	CcSEcCtD
Temsirolimus—Haematuria—Methotrexate—systemic scleroderma	0.000224	0.000509	CcSEcCtD
Temsirolimus—Vomiting—Leflunomide—systemic scleroderma	0.000223	0.000508	CcSEcCtD
Temsirolimus—Hypersensitivity—Lisinopril—systemic scleroderma	0.000222	0.000506	CcSEcCtD
Temsirolimus—Dizziness—Mycophenolic acid—systemic scleroderma	0.000221	0.000504	CcSEcCtD
Temsirolimus—Epistaxis—Methotrexate—systemic scleroderma	0.000221	0.000504	CcSEcCtD
Temsirolimus—Rash—Leflunomide—systemic scleroderma	0.000221	0.000504	CcSEcCtD
Temsirolimus—Dermatitis—Leflunomide—systemic scleroderma	0.000221	0.000503	CcSEcCtD
Temsirolimus—Mental disorder—Prednisone—systemic scleroderma	0.000221	0.000503	CcSEcCtD
Temsirolimus—Nausea—Azathioprine—systemic scleroderma	0.000221	0.000502	CcSEcCtD
Temsirolimus—Headache—Leflunomide—systemic scleroderma	0.00022	0.0005	CcSEcCtD
Temsirolimus—Malnutrition—Prednisone—systemic scleroderma	0.000219	0.000499	CcSEcCtD
Temsirolimus—Erythema—Prednisone—systemic scleroderma	0.000219	0.000499	CcSEcCtD
Temsirolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—systemic scleroderma	0.000217	0.00236	CbGpPWpGaD
Temsirolimus—Asthenia—Lisinopril—systemic scleroderma	0.000216	0.000492	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.000216	0.000492	CcSEcCtD
Temsirolimus—MTOR—Cellular responses to stress—IL1A—systemic scleroderma	0.000214	0.00233	CbGpPWpGaD
Temsirolimus—Pruritus—Lisinopril—systemic scleroderma	0.000213	0.000486	CcSEcCtD
Temsirolimus—Vomiting—Mycophenolic acid—systemic scleroderma	0.000213	0.000484	CcSEcCtD
Temsirolimus—Rash—Mycophenolic acid—systemic scleroderma	0.000211	0.00048	CcSEcCtD
Temsirolimus—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000211	0.00048	CcSEcCtD
Temsirolimus—Headache—Mycophenolic acid—systemic scleroderma	0.00021	0.000477	CcSEcCtD
Temsirolimus—Pharyngitis—Methotrexate—systemic scleroderma	0.000209	0.000476	CcSEcCtD
Temsirolimus—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000209	0.000475	CcSEcCtD
Temsirolimus—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000209	0.000475	CcSEcCtD
Temsirolimus—Nausea—Leflunomide—systemic scleroderma	0.000208	0.000474	CcSEcCtD
Temsirolimus—Urinary tract disorder—Methotrexate—systemic scleroderma	0.000208	0.000473	CcSEcCtD
Temsirolimus—Urethral disorder—Methotrexate—systemic scleroderma	0.000206	0.00047	CcSEcCtD
Temsirolimus—Diarrhoea—Lisinopril—systemic scleroderma	0.000206	0.00047	CcSEcCtD
Temsirolimus—FKBP1A—Disease—HSPG2—systemic scleroderma	0.000203	0.00221	CbGpPWpGaD
Temsirolimus—Anaemia—Prednisone—systemic scleroderma	0.000203	0.000462	CcSEcCtD
Temsirolimus—Angioedema—Prednisone—systemic scleroderma	0.0002	0.000456	CcSEcCtD
Temsirolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	0.0002	0.00217	CbGpPWpGaD
Temsirolimus—Dizziness—Lisinopril—systemic scleroderma	0.000199	0.000454	CcSEcCtD
Temsirolimus—Erythema multiforme—Methotrexate—systemic scleroderma	0.000199	0.000453	CcSEcCtD
Temsirolimus—Nausea—Mycophenolic acid—systemic scleroderma	0.000199	0.000453	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—CSK—systemic scleroderma	0.000197	0.00214	CbGpPWpGaD
Temsirolimus—Eye disorder—Methotrexate—systemic scleroderma	0.000197	0.000448	CcSEcCtD
Temsirolimus—FKBP1A—Disease—CSK—systemic scleroderma	0.000196	0.00213	CbGpPWpGaD
Temsirolimus—Cardiac disorder—Methotrexate—systemic scleroderma	0.000195	0.000445	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—SMAD7—systemic scleroderma	0.000195	0.00212	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000443	CcSEcCtD
Temsirolimus—MTOR—EGF/EGFR Signaling Pathway—NOS3—systemic scleroderma	0.000194	0.00211	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—CD247—systemic scleroderma	0.000193	0.0021	CbGpPWpGaD
Temsirolimus—MTOR—Innate Immune System—ITGAM—systemic scleroderma	0.000193	0.0021	CbGpPWpGaD
Temsirolimus—Vomiting—Lisinopril—systemic scleroderma	0.000192	0.000436	CcSEcCtD
Temsirolimus—Angiopathy—Methotrexate—systemic scleroderma	0.000191	0.000435	CcSEcCtD
Temsirolimus—Immune system disorder—Methotrexate—systemic scleroderma	0.00019	0.000433	CcSEcCtD
Temsirolimus—Rash—Lisinopril—systemic scleroderma	0.00019	0.000433	CcSEcCtD
Temsirolimus—Convulsion—Prednisone—systemic scleroderma	0.00019	0.000433	CcSEcCtD
Temsirolimus—Dermatitis—Lisinopril—systemic scleroderma	0.00019	0.000432	CcSEcCtD
Temsirolimus—Mediastinal disorder—Methotrexate—systemic scleroderma	0.00019	0.000432	CcSEcCtD
Temsirolimus—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000431	CcSEcCtD
Temsirolimus—Hypertension—Prednisone—systemic scleroderma	0.000189	0.000431	CcSEcCtD
Temsirolimus—Chills—Methotrexate—systemic scleroderma	0.000189	0.00043	CcSEcCtD
Temsirolimus—Headache—Lisinopril—systemic scleroderma	0.000189	0.00043	CcSEcCtD
Temsirolimus—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000425	CcSEcCtD
Temsirolimus—Myalgia—Prednisone—systemic scleroderma	0.000187	0.000425	CcSEcCtD
Temsirolimus—Arthralgia—Prednisone—systemic scleroderma	0.000187	0.000425	CcSEcCtD
Temsirolimus—Anxiety—Prednisone—systemic scleroderma	0.000186	0.000424	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000185	0.000422	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—CD247—systemic scleroderma	0.000185	0.00202	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—CD247—systemic scleroderma	0.000184	0.00201	CbGpPWpGaD
Temsirolimus—Mental disorder—Methotrexate—systemic scleroderma	0.000184	0.00042	CcSEcCtD
Temsirolimus—Malnutrition—Methotrexate—systemic scleroderma	0.000183	0.000417	CcSEcCtD
Temsirolimus—Erythema—Methotrexate—systemic scleroderma	0.000183	0.000417	CcSEcCtD
Temsirolimus—MTOR—Senescence and Autophagy in Cancer—TGFB1—systemic scleroderma	0.000181	0.00197	CbGpPWpGaD
Temsirolimus—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000181	0.000411	CcSEcCtD
Temsirolimus—MTOR—Innate Immune System—TNFAIP3—systemic scleroderma	0.000181	0.00197	CbGpPWpGaD
Temsirolimus—Dysgeusia—Methotrexate—systemic scleroderma	0.000179	0.000409	CcSEcCtD
Temsirolimus—Nausea—Lisinopril—systemic scleroderma	0.000179	0.000408	CcSEcCtD
Temsirolimus—Oedema—Prednisone—systemic scleroderma	0.000179	0.000408	CcSEcCtD
Temsirolimus—Anaphylactic shock—Prednisone—systemic scleroderma	0.000179	0.000408	CcSEcCtD
Temsirolimus—Infection—Prednisone—systemic scleroderma	0.000178	0.000405	CcSEcCtD
Temsirolimus—Back pain—Methotrexate—systemic scleroderma	0.000177	0.000404	CcSEcCtD
Temsirolimus—Nervous system disorder—Prednisone—systemic scleroderma	0.000176	0.0004	CcSEcCtD
Temsirolimus—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000398	CcSEcCtD
Temsirolimus—Skin disorder—Prednisone—systemic scleroderma	0.000174	0.000396	CcSEcCtD
Temsirolimus—MTOR—Signaling by SCF-KIT—MMP9—systemic scleroderma	0.000174	0.00189	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—BLK—systemic scleroderma	0.000171	0.00186	CbGpPWpGaD
Temsirolimus—Anorexia—Prednisone—systemic scleroderma	0.000171	0.000389	CcSEcCtD
Temsirolimus—Anaemia—Methotrexate—systemic scleroderma	0.000169	0.000386	CcSEcCtD
Temsirolimus—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000168	0.000382	CcSEcCtD
Temsirolimus—Rash—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000379	CcSEcCtD
Temsirolimus—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000379	CcSEcCtD
Temsirolimus—Headache—Mycophenolate mofetil—systemic scleroderma	0.000165	0.000377	CcSEcCtD
Temsirolimus—Leukopenia—Methotrexate—systemic scleroderma	0.000164	0.000374	CcSEcCtD
Temsirolimus—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000163	0.000371	CcSEcCtD
Temsirolimus—Insomnia—Prednisone—systemic scleroderma	0.000162	0.000369	CcSEcCtD
Temsirolimus—Cough—Methotrexate—systemic scleroderma	0.00016	0.000364	CcSEcCtD
Temsirolimus—Convulsion—Methotrexate—systemic scleroderma	0.000159	0.000362	CcSEcCtD
Temsirolimus—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000357	CcSEcCtD
Temsirolimus—MTOR—Disease—SMAD7—systemic scleroderma	0.000157	0.0017	CbGpPWpGaD
Temsirolimus—Arthralgia—Methotrexate—systemic scleroderma	0.000156	0.000355	CcSEcCtD
Temsirolimus—Chest pain—Methotrexate—systemic scleroderma	0.000156	0.000355	CcSEcCtD
Temsirolimus—Myalgia—Methotrexate—systemic scleroderma	0.000156	0.000355	CcSEcCtD
Temsirolimus—Decreased appetite—Prednisone—systemic scleroderma	0.000156	0.000354	CcSEcCtD
Temsirolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000155	0.000353	CcSEcCtD
Temsirolimus—Fatigue—Prednisone—systemic scleroderma	0.000154	0.000351	CcSEcCtD
Temsirolimus—Constipation—Prednisone—systemic scleroderma	0.000153	0.000349	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—RHOB—systemic scleroderma	0.000151	0.00164	CbGpPWpGaD
Temsirolimus—Anaphylactic shock—Methotrexate—systemic scleroderma	0.00015	0.000341	CcSEcCtD
Temsirolimus—Infection—Methotrexate—systemic scleroderma	0.000149	0.000338	CcSEcCtD
Temsirolimus—Nervous system disorder—Methotrexate—systemic scleroderma	0.000147	0.000334	CcSEcCtD
Temsirolimus—Thrombocytopenia—Methotrexate—systemic scleroderma	0.000146	0.000334	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000146	0.000333	CcSEcCtD
Temsirolimus—Skin disorder—Methotrexate—systemic scleroderma	0.000145	0.000331	CcSEcCtD
Temsirolimus—MTOR—Disease—TGFBI—systemic scleroderma	0.000143	0.00156	CbGpPWpGaD
Temsirolimus—Anorexia—Methotrexate—systemic scleroderma	0.000143	0.000325	CcSEcCtD
Temsirolimus—FKBP1A—Signaling Pathways—HSPG2—systemic scleroderma	0.000142	0.00155	CbGpPWpGaD
Temsirolimus—Abdominal pain—Prednisone—systemic scleroderma	0.000141	0.000322	CcSEcCtD
Temsirolimus—Body temperature increased—Prednisone—systemic scleroderma	0.000141	0.000322	CcSEcCtD
Temsirolimus—MTOR—Adaptive Immune System—CTLA4—systemic scleroderma	0.00014	0.00153	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CSK—systemic scleroderma	0.000137	0.00149	CbGpPWpGaD
Temsirolimus—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	0.000136	0.00031	CcSEcCtD
Temsirolimus—Insomnia—Methotrexate—systemic scleroderma	0.000135	0.000308	CcSEcCtD
Temsirolimus—Dyspnoea—Methotrexate—systemic scleroderma	0.000133	0.000304	CcSEcCtD
Temsirolimus—Somnolence—Methotrexate—systemic scleroderma	0.000133	0.000303	CcSEcCtD
Temsirolimus—Hypersensitivity—Prednisone—systemic scleroderma	0.000132	0.0003	CcSEcCtD
Temsirolimus—Decreased appetite—Methotrexate—systemic scleroderma	0.00013	0.000296	CcSEcCtD
Temsirolimus—Gastrointestinal disorder—Methotrexate—systemic scleroderma	0.000129	0.000294	CcSEcCtD
Temsirolimus—Fatigue—Methotrexate—systemic scleroderma	0.000129	0.000294	CcSEcCtD
Temsirolimus—Asthenia—Prednisone—systemic scleroderma	0.000128	0.000292	CcSEcCtD
Temsirolimus—Pain—Methotrexate—systemic scleroderma	0.000128	0.000291	CcSEcCtD
Temsirolimus—Pruritus—Prednisone—systemic scleroderma	0.000127	0.000288	CcSEcCtD
Temsirolimus—ABCB1—Allograft Rejection—IL1B—systemic scleroderma	0.000126	0.00137	CbGpPWpGaD
Temsirolimus—Diarrhoea—Prednisone—systemic scleroderma	0.000122	0.000279	CcSEcCtD
Temsirolimus—Gastrointestinal pain—Methotrexate—systemic scleroderma	0.000122	0.000279	CcSEcCtD
Temsirolimus—MTOR—Immune System—CSK—systemic scleroderma	0.000119	0.0013	CbGpPWpGaD
Temsirolimus—Dizziness—Prednisone—systemic scleroderma	0.000118	0.00027	CcSEcCtD
Temsirolimus—Body temperature increased—Methotrexate—systemic scleroderma	0.000118	0.000269	CcSEcCtD
Temsirolimus—Abdominal pain—Methotrexate—systemic scleroderma	0.000118	0.000269	CcSEcCtD
Temsirolimus—MTOR—Immune System—IRF5—systemic scleroderma	0.000118	0.00128	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—HLA-DQB1—systemic scleroderma	0.000116	0.00126	CbGpPWpGaD
Temsirolimus—MTOR—Disease—HSPG2—systemic scleroderma	0.000114	0.00124	CbGpPWpGaD
Temsirolimus—Vomiting—Prednisone—systemic scleroderma	0.000114	0.000259	CcSEcCtD
Temsirolimus—Rash—Prednisone—systemic scleroderma	0.000113	0.000257	CcSEcCtD
Temsirolimus—Dermatitis—Prednisone—systemic scleroderma	0.000113	0.000257	CcSEcCtD
Temsirolimus—MTOR—Immune System—IRF8—systemic scleroderma	0.000112	0.00122	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD247—systemic scleroderma	0.000112	0.00122	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—ITGAM—systemic scleroderma	0.000112	0.00122	CbGpPWpGaD
Temsirolimus—Headache—Prednisone—systemic scleroderma	0.000112	0.000255	CcSEcCtD
Temsirolimus—MTOR—Disease—CSK—systemic scleroderma	0.00011	0.0012	CbGpPWpGaD
Temsirolimus—Hypersensitivity—Methotrexate—systemic scleroderma	0.00011	0.000251	CcSEcCtD
Temsirolimus—MTOR—Signaling Pathways—SMAD7—systemic scleroderma	0.00011	0.00119	CbGpPWpGaD
Temsirolimus—MTOR—Adaptive Immune System—CD40LG—systemic scleroderma	0.000109	0.00119	CbGpPWpGaD
Temsirolimus—Asthenia—Methotrexate—systemic scleroderma	0.000107	0.000244	CcSEcCtD
Temsirolimus—Nausea—Prednisone—systemic scleroderma	0.000106	0.000242	CcSEcCtD
Temsirolimus—Pruritus—Methotrexate—systemic scleroderma	0.000106	0.000241	CcSEcCtD
Temsirolimus—MTOR—Immune System—TNFAIP3—systemic scleroderma	0.000105	0.00114	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—BLK—systemic scleroderma	0.000104	0.00113	CbGpPWpGaD
Temsirolimus—MTOR—Disease—CD247—systemic scleroderma	0.000104	0.00113	CbGpPWpGaD
Temsirolimus—Diarrhoea—Methotrexate—systemic scleroderma	0.000102	0.000233	CcSEcCtD
Temsirolimus—Dizziness—Methotrexate—systemic scleroderma	9.89e-05	0.000225	CcSEcCtD
Temsirolimus—ABCB1—Allograft Rejection—TGFB1—systemic scleroderma	9.79e-05	0.00107	CbGpPWpGaD
Temsirolimus—Vomiting—Methotrexate—systemic scleroderma	9.51e-05	0.000217	CcSEcCtD
Temsirolimus—Rash—Methotrexate—systemic scleroderma	9.43e-05	0.000215	CcSEcCtD
Temsirolimus—Dermatitis—Methotrexate—systemic scleroderma	9.42e-05	0.000215	CcSEcCtD
Temsirolimus—Headache—Methotrexate—systemic scleroderma	9.37e-05	0.000213	CcSEcCtD
Temsirolimus—Nausea—Methotrexate—systemic scleroderma	8.88e-05	0.000202	CcSEcCtD
Temsirolimus—MTOR—Immune System—CTLA4—systemic scleroderma	8.51e-05	0.000926	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—RHOB—systemic scleroderma	8.48e-05	0.000923	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—HSPG2—systemic scleroderma	8e-05	0.00087	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CSK—systemic scleroderma	7.73e-05	0.000841	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—EDN1—systemic scleroderma	7.7e-05	0.000838	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—HSPG2—systemic scleroderma	7.55e-05	0.000822	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—HLA-DQB1—systemic scleroderma	7.01e-05	0.000763	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—NOS3—systemic scleroderma	6.7e-05	0.000729	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL1A—systemic scleroderma	6.66e-05	0.000725	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—CD40LG—systemic scleroderma	6.62e-05	0.000721	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—CTGF—systemic scleroderma	5.72e-05	0.000623	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—HSPG2—systemic scleroderma	5.46e-05	0.000594	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—CCL2—systemic scleroderma	5.26e-05	0.000573	CbGpPWpGaD
Temsirolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TGFB1—systemic scleroderma	4.83e-05	0.000526	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—NOS3—systemic scleroderma	4.69e-05	0.000511	CbGpPWpGaD
Temsirolimus—FKBP1A—Disease—TGFB1—systemic scleroderma	4.43e-05	0.000482	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—EDN1—systemic scleroderma	4.33e-05	0.000471	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—CTGF—systemic scleroderma	4.14e-05	0.00045	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—HSPG2—systemic scleroderma	4.12e-05	0.000448	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—HSPG2—systemic scleroderma	3.88e-05	0.000422	CbGpPWpGaD
Temsirolimus—MTOR—Disease—NOS3—systemic scleroderma	3.77e-05	0.00041	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—MMP9—systemic scleroderma	3.76e-05	0.00041	CbGpPWpGaD
Temsirolimus—MTOR—Immune System—IL1B—systemic scleroderma	3.47e-05	0.000378	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—CTGF—systemic scleroderma	3.12e-05	0.00034	CbGpPWpGaD
Temsirolimus—FKBP1A—Signaling Pathways—TGFB1—systemic scleroderma	3.1e-05	0.000338	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—CCL2—systemic scleroderma	2.96e-05	0.000322	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—CTGF—systemic scleroderma	2.94e-05	0.00032	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—NOS3—systemic scleroderma	2.64e-05	0.000287	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—HSPG2—systemic scleroderma	2.54e-05	0.000276	CbGpPWpGaD
Temsirolimus—MTOR—Disease—TGFB1—systemic scleroderma	2.49e-05	0.000271	CbGpPWpGaD
Temsirolimus—CYP3A7—Metabolism—NOS3—systemic scleroderma	2.49e-05	0.000271	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—MMP9—systemic scleroderma	2.12e-05	0.00023	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—CTGF—systemic scleroderma	1.92e-05	0.000209	CbGpPWpGaD
Temsirolimus—CYP3A5—Metabolism—NOS3—systemic scleroderma	1.8e-05	0.000196	CbGpPWpGaD
Temsirolimus—MTOR—Signaling Pathways—TGFB1—systemic scleroderma	1.74e-05	0.00019	CbGpPWpGaD
Temsirolimus—ABCB1—Metabolism—NOS3—systemic scleroderma	1.36e-05	0.000148	CbGpPWpGaD
Temsirolimus—CYP2D6—Metabolism—NOS3—systemic scleroderma	1.28e-05	0.000139	CbGpPWpGaD
Temsirolimus—CYP3A4—Metabolism—NOS3—systemic scleroderma	8.37e-06	9.11e-05	CbGpPWpGaD
